IGF-1 receptor inhibitors in clinical trials - Early lessons

S. John Weroha, Paul Haluska

Research output: Contribution to journalReview article

136 Scopus citations

Abstract

The insulin-like growth factor pathway plays a major role in cancer cell proliferation, survival and resistance to anti-cancer therapies in many human malignancies, including breast cancer. As a key signaling component of IGF system, the IGF-1 receptor is the target of several investigational agents in clinical and pre-clinical development. This review will focus on the rationale for targeting the IGF-1 receptor and other components of the IGF-1 system. In addition, we will examine the role of IGF-1 signaling in resistance to clinically important breast cancer therapies, including cytotoxic chemotherapy, hormonal therapy and erbB targeted agents. We will also review the completed and ongoing clinical investigations with IGF-1 receptors inhibitors to date and the utility of these early data in designing future breast cancer studies with IGF-1 signaling inhibition strategies.

Original languageEnglish (US)
Pages (from-to)471-483
Number of pages13
JournalJournal of Mammary Gland Biology and Neoplasia
Volume13
Issue number4
DOIs
StatePublished - Nov 20 2008

Keywords

  • Clinical trials - Phase I
  • Clinical trials - Phase II
  • Drug resistance
  • IGF-1R inhibition
  • IGFType I
  • Monoclonal antibody
  • Receptor
  • Receptor crosstalk
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'IGF-1 receptor inhibitors in clinical trials - Early lessons'. Together they form a unique fingerprint.

  • Cite this